<DOC>
	<DOCNO>NCT00106847</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness schedule need treatment psoriasis infliximab . Infliximab ( Remicade ) target specific proteins body 's immune system help control development inflammation help reduce painful disease .</brief_summary>
	<brief_title>A Study Safety Effectiveness Infliximab Patients With Plaque-type Psoriasis</brief_title>
	<detailed_description>This phase III , multicenter , randomize ( patient assign different treatment base chance ) , double-blind ( neither patient physician know whether drug placebo take , dosage ) , placebo-controlled trial evaluate effectiveness safety schedule need treatment infliximab patient plaque-type psoriasis . This study also help determine way use infliximab treat patient psoriasis . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive infusion either placebo , 3mg/kg 5 mg/kg infliximab ( Remicade ) week 0 , 2 , 6 14 , 18 , 22 , 26 , 30 , 34 , 38 , 42 46 . Patients receive either 3mg/kg , 5 mg/kg placebo infusion week 0 , 2 , 6 . The 3mg/kg 5 mg/kg infliximab group receive either every 8 week infusion infusion need psoriasis le 75 % improved baseline . The placebo patient begin infliximab week 16 , 18 22 follow every 8 week infusion .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Parapsoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients diagnosis plaquetype psoriasis least 6 month Patients plaquetype psoriasis cover least 10 % body Patients nonplaque form psoriasis Patients current druginduced psoriasis Patients pregnant , nursing , plan pregnancy ( men woman ) within 18 month enrollment Patients previous treatment infliximab therapeutic agent target reduce tumor necrosis factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>plaque-type psoriasis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>drug safety</keyword>
	<keyword>drug efficacy</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>induction therapy</keyword>
	<keyword>remicade</keyword>
</DOC>